ReviewCurrent opinion in immunology2025
Novel approaches to prevent or cure allergic diseases.
Review in Current opinion in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Prevention remains a critical goal to improve quality of life, given the chronic nature of allergic conditions and the interplay between them contributing to the atopic march. In this review, we will highlight key novel approaches to preventing allergic disease using a top-down approach (primary to secondary to tertiary). Significant advancements in the field have resulted in cutting-edge therapies and options for patients to optimize their health and quality of life. These include early introduction of allergenic foods; oral, sublingual, epicutaneous, and subcutaneous immunotherapy; biologic therapy; and elimination of allergen or irritant skin exposures. Further research and developments are necessary to prevent the atopic march and continue the progression of diagnostic and treatment modalities in allergic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.